esports events

esports events WILMINGTON, N.C. (AP) — Donovan Newby had 18 points in UNC Wilmington's 78-69 victory over Marshall on Saturday. Read this article for free: Already have an account? To continue reading, please subscribe: * WILMINGTON, N.C. (AP) — Donovan Newby had 18 points in UNC Wilmington's 78-69 victory over Marshall on Saturday. Read unlimited articles for free today: Already have an account? WILMINGTON, N.C. (AP) — Donovan Newby had 18 points in UNC Wilmington’s 78-69 victory over Marshall on Saturday. Newby shot 5 for 10 (0 for 3 from 3-point range) and 8 of 11 from the free-throw line for the Seahawks (7-2). Sean Moore scored 14 points while shooting 6 for 11, including 2 for 3 from beyond the arc and added 16 rebounds. Khamari McGriff shot 5 of 6 from the field and 3 for 3 from the line to finish with 13 points, while adding six rebounds. The Thundering Herd (5-4) were led in scoring by Mikal Dawson, who finished with 12 points and two steals. Marshall also got 10 points and nine rebounds from Nate Martin. Dezayne Mingo also had 10 points, eight rebounds and five assists. UNC Wilmington took the lead with 12:17 to go in the first half and did not give it up. The score was 44-34 at halftime, with Moore racking up 12 points. UNC Wilmington was outscored by Marshall in the second half by one point, with Newby scoring a team-high 12 points after halftime. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. Advertisement

( MENAFN - The Peninsula) AFP Kyiv: Ukrainian President Volodymyr Zelensky said on Friday that "several" wounded North Korean soldiers died after being captured by Ukrainian forces, as he accused Russia of throwing them into battle with "minimal protection". Ukraine and its western allies say North Korea has sent thousands of soldiers to support Russia's army, in what is seen as a major escalation in the nearly three-year war following Moscow's 2022 invasion. "Today there were reports about several soldiers from North Korea. Our soldiers managed to take them prisoner. But they were very seriously wounded and could not be resuscitated," Zelensky said in an evening address posted on social media. South Korea's spy agency said earlier on Friday that a North Korean soldier who was captured while fighting in Russia's war against Ukraine had died of his wounds. Zelensky did not specify how many North Koreans had died after being captured by Ukrainian troops. Zelensky had earlier said that nearly 3,000 North Korean soldiers had been "killed or wounded" so far as they joined Russia's forces in combat in its western Kursk border region, where Ukraine mounted a shock incursion in August. South Korea's intelligence service had previously put the number of killed or wounded North Koreans at 1,000, saying the high casualty rate could be down to an unfamiliar battlefield environment and their lack of capability to counter drone attacks. The White House on Friday confirmed the South Korean estimates, saying that Pyongyang's troops were being sent to their deaths in futile attacks by generals who see them as "expendable". "We also have reports of North Korean soldiers taking their own lives rather than surrendering to Ukrainian forces, likely out of fear of reprisal against their families in North Korea in the event that they're captured," National Security Council spokesman John Kirby told reporters. Putin message to Kim North Korea and Russia have strengthened their military ties since Moscow's invasion of Ukraine in February 2022. A landmark defence pact between Pyongyang and Moscow signed in June came into force this month, with Russian President Vladimir Putin hailing it as a "breakthrough document". North Korean state media said on Friday that Putin sent a New Year's message to North Korean leader Kim Jong Un, saying: "The bilateral ties between our two countries have been elevated after our talks in June in Pyongyang." Seoul's military believes that North Korea was seeking to modernise its conventional warfare capabilities through combat experience gained in the Russia-Ukraine war. NATO chief Mark Rutte had also said that Moscow was providing support to Pyongyang's missile and nuclear programmes in exchange for the troops. South Korea's Joint Chiefs of Staff said Monday that Pyongyang is reportedly "preparing for the rotation or additional deployment of soldiers" and supplying "240mm rocket launchers and 170mm self-propelled artillery" to the Russian army. Pyongyang's involvement in Russia's war against Ukraine had prompted warnings from Seoul. South Korea's President Yoon Suk Yeol, currently suspended, said in November that Seoul was "not ruling out the possibility of providing weapons" to Kyiv, which would mark a major shift to a long-standing policy barring the sale of weapons to countries in active conflict. MENAFN27122024000063011010ID1109036079 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.None

Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox Study stopped enrolling patients in all study arms Results affirm tecovirimat’s strong safety profile Efficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA’s tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients. Data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints. “Antivirals are most effective when administered early in the course of an infection and tend to demonstrate the greatest benefit in patients with more severe disease. The STOMP results are not unexpected as the study design was similar to the PALM007 study except it was in patients with mild to moderate clade II mpox compared to patients with clade I mpox. It is important to note that approximately 75% of mpox patients in the randomized arms of the STOMP trial received tecovirimat more than five days after symptom onset, and higher risk patients were included in an open-label arm,” stated Diem Nguyen, Chief Executive Officer. Tecovirimat, also known as TPOXX, was developed in partnership with the U.S. Government and approved by the U.S. Food and Drug Administration to treat smallpox—a virus closely related to, but far more serious than, mpox. TPOXX was approved in 2018 based on data from 12 clinical trials of oral TPOXX in 700 healthy human volunteers, which showed no drug-related serious adverse events. Four pivotal trials in non-human primates (NHPs) and two pivotal trials in rabbits demonstrated that TPOXX significantly reduced both mortality and viral load in NHP infected with mpox virus and in rabbits infected with rabbitpox virus. The results of the animal efficacy studies were published in the July 5, 2018 issue of the New England Journal of Medicine . “Tecovirimat’s mechanism of action is driven by halting viral transmission. Once virus is present in the system, the body’s natural immune system plays a central role in clearing it, typically within two to four weeks in immune competent patients. Research results thus far indicate that early treatment with tecovirimat including post-exposure prophylaxis and treatment in severe cases may offer the greatest potential for patient benefit,” stated Dennis Hruby, Chief Scientific Officer. Additionally, in this study, tecovirimat exhibited a safety profile comparable to placebo. These safety results are consistent with prior studies and further support the strong safety profile that has been observed with tecovirimat over the past 15 years. Dr. Nguyen continued, “We thank our partners, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH), the patients who participated in this trial, and the investigators who supported this trial. Their unwavering dedication to public health has been instrumental in advancing our understanding of mpox and tecovirimat.” Three randomized clinical trials, UNITY (Switzerland, Brazil, Argentina), Platinum-CAN (Canada), and EPOXI (EU), are enrolling mpox patients. Given the STOMP and PALM007 results and the design similarities across these mpox trials, the Company believes these ongoing trials are likely to yield similar results. About the STOMP Clinical Trial in Mpox The STOMP study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive mpox disease. Beginning in September 2022, the study enrolled participants with mpox from Argentina, Brazil, Japan, Mexico, Peru, Thailand, and the United States, including Puerto Rico, who had symptoms for less than 14 days. Participants were randomly (2:1) assigned to receive tecovirimat or a placebo for 14 days. The number of capsules and frequency of dosage were based on patient weight. Participants with severe disease, certain skin conditions, or significantly suppressed immune systems received open-label tecovirimat rather than being randomized. The study monitored participants’ safety across randomized and open label arms. In the randomized arms, STOMP examined the time to full mpox lesion resolution, viral clearance, and study participants’ reports of pain. Participants were followed for 28 days with a study site visit at day 29 and then again at day 57 for possible recrudescence of infection. About SIGA SIGA Technologies (SIGA) (NASDAQ: SIGA) is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the efficacy of tecovirimat to treat mpox in certain patient populations and the results of ongoing mpox clinical studies. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,” “should,” “target,” “goal,” “potential” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that BARDA elects, in its sole discretion as permitted under the 75A50118C00019 BARDA Contract (the “BARDA Contract”), not to exercise the remaining unexercised option under the BARDA Contract, (ii) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (iii) the risk that the BARDA Contract or U.S. Department of Defense contracts are modified or canceled at the request or requirement of, or SIGA is not able to enter into new contracts to supply TPOXX to, the U.S. Government, (iv) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally, (v) the risk that potential products, including potential alternative uses or formulations of TPOXX that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (vi) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (viii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (ix) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (x) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (xi) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xii) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xiii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiv) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xv) risks associated with actions or uncertainties surrounding the debt ceiling, (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, and (xvii) risks associated with responding to an mpox outbreak, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov . All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Read this article for free: Already have an account? To continue reading, please subscribe: * NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Read unlimited articles for free today: Already have an account? NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Scrim, a 17-pound mutt that’s mostly terrier, has become a folk hero, inspiring tattoos, T-shirts and even a ballad as he eludes capture from the posse of volunteers. And like any antihero, Scrim has a backstory: Rescued from semi-feral life at a trailer park and adopted from a shelter, the dog broke loose in April and scurried around the city until he was cornered in October and brought to a new home. Weeks later, he’d had enough. Scrim leaped out of a second-story window, a desperate act recorded in a now-viral video. Since then, despite a stream of daily sightings, he’s roamed free. The dog’s fans include Myra and Steve Foster, who wrote “Ode to Scrim” to the tune of Ricky Nelson’s 1961 hit, “I’m a Travelin’ Man.” “I’m a travelin’ dog and I’ve made a lot of stops/All over this town...” Leading the recapture effort is Michelle Cheramie, a 55-year-old former information technology professional. She lost everything — home, car, possessions — in Hurricane Katrina in 2005, and in the aftermath, found her calling rescuing pets. “I was like, ‘This is what I should be doing,’” Cheramie said. “I was born to rescue.” She launched Zeus’ Rescues, a nonprofit shelter that now averages 600 cat and dog adoptions a year and offers free pet food to anyone who needs it. She helped Scrim find the home he first escaped from. It was Cheramie’s window Scrim leaped from in November. She’s resumed her relentless mission since then, posting flyers on telephone poles and logging social media updates on his reported whereabouts. She’s invested thousands of dollars on wildlife cameras, thermal sensors and other gear. She took a course offered by the San Diego Zoo on the finer points of tranquilizing animals. And she’s developed a network of volunteers — the kind of neighbors who are willing to grid-search a city at 3 a.m. “...And at every stop I own the heart, of at least one lovely ... “ People like writer David W. Brown, who manages a crowd-sourced Google Map of all known Scrim sightings. He says the search has galvanized residents from all walks of life to come together. As they search for Scrim, they hand out supplies to people in need. “Being a member of the community is seeing problems and doing what you can to make life a little better for the people around here and the animals around you,” Brown said. And neighbors like Tammy Murray, who had to close her furniture store and lost her father to Parkinson’s disease. This search, she says, got her mojo back. “Literally, for months, I’ve done nothing but hunt this dog,” said Murray, 53. “I feel like Wile E. Coyote on a daily basis with him.” Murray drives the Zeus’ Rescues’ van towards reported Scrim sightings. She also handles a tactical net launcher, which looks like an oversized flashlight and once misfired, shattering the van’s window as Scrim sped away. After realizing Scrim had come to recognize the sound of the van’s diesel engine, Murray switched to a Vespa scooter, for stealth. “...If you’re ever in the 9th Ward stop and see/My cute little mini poodle ...” Near-misses have been tantalizing. The search party spotted Scrim napping beneath an elevated house, and wrapped construction netting around the perimeter, but an over-eager volunteer broke ranks and dashed forward, leaving an opening Scrim slipped through. Scrim’s repeated escapades have prompted near-daily local media coverage and a devoted online following. Cheramie can relate. “We’re all running from something or to something. He’s doing that too,” she said. Cheramie’s team dreams of placing the pooch in a safe and loving environment. But a social media chorus growing under the hashtag #FreeScrim has other ideas — they say the runaway should be allowed a life of self-determination. The animal rescue volunteers consider that misguided. “The streets of New Orleans are not the place for a dog to be free,” Cheramie said. “It’s too dangerous.” “... and my Shar-Pei doll down in old Treme/Waits for my return ...” Scrim was a mess when Cheramie briefly recaptured him in October, with matted fur, missing teeth and a tattered ear. His trembling body was scraped and bruised, and punctured by multiple projectiles. A vet removed one, but decided against operating to take out a possible bullet. The dog initially appeared content indoors, sitting in Cheramie’s lap or napping beside her bed. Then while she was out one day, Scrim chewed through a mesh screen, dropped 13 feet to the ground and squeezed through a gap in the fence, trotting away. Murray said Cheramie’s four cats probably spooked him. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. “I wholeheartedly believe the gangster-ass cats were messing with him,” Murray said. Cheramie thinks they may have gotten territorial. Devastated but undeterred, the pair is reassessing where Scrim might fit best — maybe a secure animal sanctuary with big outdoor spaces where other dogs can keep him company. Somewhere, Murray says, “where he can just breathe and be.” ___ Brook is a corps member for The Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues. Follow Brook on the social platform X: @jack_brook96 Advertisement Advertisement

The Jacksonville Jaguars (2-10) visit the Tennessee Titans (3-9) on Sunday, December 8, 2024 at Nissan Stadium and will attempt to break a five-game losing streak. Here are best bets recommendations. BetMGM is one of the most trusted Sportsbooks in the nation. Start with as little as $1 and place your bets today . Don’t miss a touchdown this NFL season. Catch every score with NFL RedZone on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Sign up today and watch seven hours of commercial-free football from every NFL game every Sunday. Think you know who will win the game? Sign up at BetMGM and place your bet today. Want to bet on this game’s spread? Head to BetMGM and place your wager today. Want to bet on the over/under in this matchup? Make your wager at BetMGM . Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER .‘The Aftermath of War’ by Jean-Paul Sartre | Excerpt